Diffuse Large B-Cell Lymphoma – VJRegenMed

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

Anya Kerkache — Thu, 09 Mar 2023 11:31:46 +0000

Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, gives an update on a Phase I study of rapcabtagene autoleucel in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Shah explains that this next-generation CD19 CAR-T therapy has been manufactured using T-Charge, which allows this product to be manufactured faster than other CAR-T therapies, thus helping it to preserve T cell stemness, decrease the dose of infused CAR-Ts, and increase its overall quality. The study identified a safe dose level for further investigations and reported low rates of cytokine release syndrome (CRS). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

Anya Kerkache — Thu, 26 Jan 2023 12:12:01 +0000

Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL

Anya Kerkache — Thu, 26 Jan 2023 12:11:30 +0000

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, reports results from the CARBON Phase I dose-escalation study (NCT04035434), testing the safety and efficacy of a novel allogeneic CRISPR-Cas9-engineered CAR-T product, CTX110, in heavily pre-treated patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The study reported that the CAR-Ts showed clinical activity with the ability to expand in the body, and a low risk of graft-versus-host disease (GvHD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Mechanisms of resistance to CAR T-cell therapies

admin_vjr_user — Tue, 18 Jan 2022 11:12:17 +0000

John Rossi, MS, CERo Therapeutics, San Francisco, CA, discusses mechanisms of resistance and relapse in chimeric antigen receptor (CAR) T-cell therapies. T cells of patients with leukemia, lymphoma or non-Hodgkin lymphoma who have previously received multiple lines of treatment will have a lower proliferative capability and consequently have worse outcomes. Patient response to lymphodepletion therapy, as well as the tumor microenvironment can additionally determine efficacy of CAR T-cell therapies, and tumors can exhibit an immune desert phenotype during relapse, making treatment more difficult. This interview took place at the 2021 CAR-TCR Summit 2021.

CAR-T in DLBCL: 4-year follow-up data from ZUMA-1

Marta Palhas — Fri, 26 Feb 2021 14:08:28 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.

The future of CAR T-cell therapy in lymphoma

admin_vjr_user — Fri, 26 Feb 2021 14:08:21 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the future directions of CAR T-cell therapy in lymphoma. The availability of CAR-T has modified the treatment algorithm for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Indications for CAR T-cell therapy will likely expand to earlier lines of treatment and other lymphomas. Dr Sureda is looking forward to the data from three Phase III clinical trials comparing CAR T-cell therapies with autologous stem cell transplantation in patients with primary refractory disease. Additionally, strategies to improve efficacy and toxicity are certainly desirable. This interview took place during the 3rd European CAR T-cell Meeting.

Liso-cel for R/R large B-cell lymphoma

Marta Palhas — Fri, 26 Feb 2021 14:08:19 +0000

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, discusses the recent FDA approval of lisocabtagene maraleucel (liso-cel) for relapsed or refractory (R/R) large B-cell lymphoma. Prof. Jäger considers this approval another milestone in the lymphoma field that now has three CAR-T products available. The approval of liso-cel in Europe is expected soon. This interview took place during the 3rd European CAR T-cell Meeting.

Real-world efficacy & safety data: CAR-T in DLBCL

admin_vjr_user — Thu, 08 Oct 2020 14:08:13 +0000

Matthew Frigault, MD, Massachusetts General Hospital, Boston, MA, comments on the key clinical trials involved in CAR T-cell therapy for the treatment of refractory diffuse large B-Cell lymphoma (DLBCL). This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Challenges associated with CAR T-cell production

admin_vjr_user — Thu, 08 Oct 2020 14:08:12 +0000

Valentín Ortiz-Maldonado, MD, Hospital Clinic, Barcelona, Spain, discusses challenges associated with CAR T-cell production. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

Selecting DLBCL patients for CAR T-cell therapies

admin_vjr_user — Thu, 08 Oct 2020 14:08:11 +0000

Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses how patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) are selected for CAR T-cell therapies and the associated challenges. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).